Human peripheral osteoclast-precursor-development patterns reveal the significance of RPS17-dependent ribosome synthesis to Ankylosing Spondylitis lesions

Abstract

Osteoclast-development patterns and their alterations across Ankylosing Spondylitis (AS) conditions are mysterious, making AS treatment difficult. Our study aims to clarify osteoclast-precursor (OCP) development patterns from monocytes and their variations under AS conditions. We performed single-cell transcriptomics in peripheral blood mononuclear cells (PBMCs) from healthy donors and AS patients in the early, aggravated and remission stages. After monocytic reclustering, OCP-development patterns and the alterations upon AS onset and different outcomes were revealed based on single-cell trajectory. The trajectories revealed two monocyte states with strong OCP features, and AS pathogenesis was characterized by their reduction. Ribosome synthesis was considered the essential function for the development towards OCP-featured states, and this function and its representative molecule, RPS17, showed a decreasing trend with AS onset and outcomes. Histology assessment showed that RPS17 underexpression participated in AS inflammatory osteogenesis and ankylosing destruction. Conditional knockout of RPS17 ameliorated ovariectomy-induced bone loss and enhanced osteoclastogenesis, and RPS17 overexpression improved the phenotype of AS-like mice. Importantly, local injection of RPS17-overexpressed monocytic OCPs markedly ameliorated the joint alterations of AS-like mice without promoting bone loss; this was associated with enhanced osteoclastogenesis adjacent to the articular surface and T-cell-suppressive property in monocytic OCPs. Overall, the evolution of monocytes towards OCP-lineage fate mainly depends on ribosome synthesis, and OCP-development disorder participates in AS lesions due to a reduction in RPS17-dependent ribosome synthesis. Notably, RPS17-overexpressed monocytic OCPs have translational potential in preventing and treating AS peripheral lesions.

References

[1] Mauro D, et al. . Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. Nat. Rev. Rheumatol., 2021, 17: 387-404.

[2] Yi K, et al. . Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40–positive and glucocorticoid-induced tumor necrosis factor receptor–positive pathogenic Th17 cells. Arthritis Rheumatol., 2023, 75: 1176-1186.

[3] Rudwaleit M, et al. . Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology, 2009, 48: 551-557.

[4] Bleil J, et al. . Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. Arthritis Rheumatol., 2014, 66: 1745-1754.

[5] Ortolan A, et al. . Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann. Rheum. Dis., 2023, 82: 142-152.

[6] Rudwaleit M, Landewé R, Sieper J. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med., 2016, 375: 1302-1303.

[7] Li Z, et al. . Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis. Ann. Rheum. Dis., 2021, 80: 891-902.

[8] Yu T, et al. . Chondrogenesis mediates progression of ankylosing spondylitis through heterotopic ossification. Bone Res., 2021, 9: 19

[9] Zheng G, et al. . A novel Anti-ROS osteoblast-specific delivery system for ankylosing spondylitis treatment via suppression of both inflammation and pathological new bone formation. J. Nanobiotechnol., 2023, 21168

[10] Sobacchi C, Abinun M. Osteoclast-poor osteopetrosis. Bone, 2022, 164: 116541

[11] Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat. Rev. Endocrinol., 2013, 9: 522-536.

[12] Neidhart M, et al. . Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann. Rheum. Dis., 2009, 68: 1334-1339.

[13] Kwon OC, et al. . Negative regulation of osteoclast commitment by intracellular protein phosphatase magnesium-dependent 1A. Arthritis Rheumatol., 2020, 72: 750-760.

[14] Hayer S, et al. . Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. Ann. Rheum. Dis., 2010, 69: 1403-1406.

[15] Liu J, et al. . A rare variant of RNF123 in familial ankylosing spondylitis causes dysfunction of osteoclast formation. Rheumatology, 2020, 59: 1174-1177.

[16] Liu W, et al. . Abnormal inhibition of osteoclastogenesis by mesenchymal stem cells through the miR-4284/CXCL5 axis in ankylosing spondylitis. Cell Death Dis., 2019, 10188

[17] Martínez-Ramos S, Rafael-Vidal C, Pego-Reigosa JM, García S. Monocytes and macrophages in spondyloarthritis: functional roles and effects of current therapies. Cells, 2022, 11: 515

[18] Xue J, et al. . CD14⁺ CD16⁻ monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK. Arthritis Res. Ther., 2020, 22: 1-11.

[19] Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res. Ther., 2006, 8: 1-14.

[20] Caparbo VF, Saad CG, Moraes J, de Brum-Fernandes AJ, Pereira RMR. Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio. Osteoporos. Int., 2018, 29: 2565-2573.

[21] Villani AC, et al. . Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science, 2017, 356eaah4573

[22] Merah-Mourah F, Cohen S, Charron D, Mooney N, Haziot A. Identification of novel human monocyte subsets and evidence for phenotypic groups defined by interindividual variations of expression of adhesion molecules. Sci. Rep., 2020, 104397

[23] Liu P, et al. . Glucocorticoid-induced expansion of classical monocytes contributes to bone loss. Exp. Mol. Med., 2022, 54: 765-776.

[24] Doi K, et al. . Role of lysine-specific demethylase 1 in metabolically integrating osteoclast differentiation and inflammatory bone resorption through hypoxia-inducible factor 1α and E2F1. Arthritis Rheumatol., 2022, 74: 948-960.

[25] Kollet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu. Rev. Immunol., 2007, 25: 51-69.

[26] Amano S, Kawakami K, Iwahashi H, Kitano S, Hanazawa S. Functional role of endogenous CD14 in lipopolysaccharide-stimulated bone resorption. J. Cell. Physiol., 1997, 173: 301-309.

[27] Taylor RM, et al. . CD14-mononuclear stromal cells support (CD14+) monocyte–osteoclast differentiation in aneurysmal bone cyst. Lab. Invest., 2012, 92: 600-605.

[28] Meirow Y, et al. . Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss. Bone Res., 2022, 10: 36

[29] Nishida M, Saegusa J, Tanaka S, Morinobu A. S100A12 facilitates osteoclast differentiation from human monocytes. PLoS One, 2018, 13: e0204140

[30] Jacome-Galarza CE, et al. . Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery. J. Bone Miner. Res., 2013, 28: 1203-1213.

[31] Yao Z, et al. . Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem., 2006, 281: 11846-11855.

[32] Charles JF, et al. . Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest., 2012, 122: 4592-4605.

[33] Wu H, et al. . Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci. Transl. Med., 2016, 8: 331ra40

[34] Sangaletti S, et al. . SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities. Front. Immunol., 2019, 10: 1369

[35] Jeon C, et al. . Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. Int. Immunopharmacol., 2023, 118: 110132

[36] Li D, et al. . Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun., 2016, 710872

[37] Muto A, et al. . Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J. Bone Miner. Res., 2011, 26: 2978-2990.

[38] Sanchez CG, et al. . Regulation of ribosome biogenesis and protein synthesis controls germline stem cell differentiation. Cell Stem Cell, 2016, 18: 276-290.

[39] Saba JA, Liakath-Ali K, Green R, Watt FM. Translational control of stem cell function. Nat. Rev. Mol. Cell Biol., 2021, 22: 671-690.

[40] Singh S, Vanden Broeck A, Miller L, Chaker-Margot M, Klinge S. Nucleolar maturation of the human small subunit processome. Science, 2021, 373: eabj5338

[41] Hasegawa T, et al. . Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat. Immunol., 2019, 20: 1631-1643.

[42] Umar S, et al. . CCL25 and CCR9 is a unique pathway that potentiates pannus formation by remodeling RA macrophages into mature osteoclasts. Eur. J. Immunol., 2021, 51: 903-914.

[43] Ruutu M, et al. . β-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheumatol., 2012, 64: 2211-2222.

Funding

National Science Foundation of China | International Cooperation and Exchange Programme(81820108020)

China Postdoctoral Science Foundation(2022M710702)

Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation)(2023J011209)

Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province)(2023Y9601)

Fujian Provincial Health Technology Project (2023GGA004)

National Science Foundation of China | Major Research Plan(81991510)

National Natural Science Foundation of China (National Science Foundation of China)(82472473)

Major Scientific Research Project of Health in Fujian Province (20212D01003)

RIGHTS & PERMISSIONS

The Author(s)